Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New Press Release - Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

<< Previous

Bullboard Posts

Next >>

Comment by Legit62on Sep 03, 2024 10:05am

202 Views

Post# 36206030

RE:RE:RE:New Press Release - Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

Totally agree Oden6570, but nothing happens until we get BTD and AA IMO, lot of talk and showcasing but we are not derisked in FDA terms yet and until then just useless PRS ,again IMO. i want to hear about OBTAINED FINANCING or JVs , until then just the wait game on our phenomenal technology

<< Previous

Bullboard Posts

Next >>

Nvidia reports record revenue in Q3